InterMune (nasdaq)ITMN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: hdl who wrote (501)	11/6/2013 3:04:30 PM
From: Biotech Jim	Read Replies (1) of 508

One Q on ITMN is where will the share price stabilize? Will it be in the low $12s, or come back to the $10s area? I lucked out and sold my remaining long term shares the day after they announced the secondary (ie, yesterday). I did have a buy order in at $12.48, but cancelled it due to the toppyness of biotech stocks and thought the price might go lower. The other Q is how the perfenidone (Esbriet) ASCEND trial will do? Pretty straightforward endpoint of FVC at 52 weeks compared to predrug status. hdl, do you a prediction on the ASCEND trial outcome, and whether the FDA will accept the results if positive, since there is no SPA in hand? Dramatic unmet medical need for an IPF drug. A summary of the previous Capacity studies are provided in this link: drugs.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next